MPE participated in the discussion panel of the documentary premiere

Listen the voice of myeloma patients in documentary “My myeloma: ready for the steps ahead”

MyelomaLeave a comment

March is Multiple Myeloma Awareness Month. This incurable disease affects increasingly young adult generation. In Europe, more than 50.900 people were diagnosed with myeloma in 2020[1].   Patient organisations from Central and Eastern Europe (CEE) have joined forces to create the documentary My myeloma: ready for the steps ahead, which premiered on 21th of March 2023 in Ljubljana, Slovenia. The premiere was attended by patient representatives, patient organisations, healthcare professionals and media representatives, who expressed…

T2EVOLVE and QUALITOP launch European patient survey on CAR-T treatment

CAR-T, MyelomaLeave a comment

THE IMI T2EVOLVE Project and the Horizon 2020 QUALITOP Project have launched a European patient survey on CAR-T treatment. The survey aims to inform on patient and carer experiences and challenges of receiving CAR-T and to identify information needs and gaps across Europe. The results of the survey will be used for research purposes and published anonymously on project partner websites as well as in academic journals.   The T2EVOLVE-QUALITOP European patient survey on CAR-T…

Volunteers of AMEN protesting outside the “Health Basket” Committee conference to include Daratumumab for NDMM patients (December 2021)

Daratumumab approved for first line treatment in Israel

MPE, MyelomaLeave a comment

Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel.    “Health Basket” Each year, the Israel Ministry of Health nominates a Health Committee to discuss and recommend approval and extension for a new “health basket,” which includes all the services, medications, supplies,…

Study shows the importance of vaccination for myeloma patients

MyelomaLeave a comment

Influenza (i.e. “flu”) and pneumococcal vaccinations positively impact the outcomes of myeloma patients. This is the central conclusion in the article Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma (MM) Patients: Influenza and Pneumococcal Vaccination in MM, published in Clinical Lymphoma, Myeloma and Leukaemia. The article outlines an analysis of data gathered from INSIGHT-MM, a global real-world study involving myeloma patients, looking at influenza and pneumococcal vaccination rates of patients and…

Talquetamab generates high response rate in patients with hard-to-treat myeloma

Conferences, Myeloma, UncategorizedLeave a comment

NEW ORLEANS. New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition focuses on talquetamab in patients with Relapsed/Refractory myeloma. In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy for myeloma, saw a significant reduction in cancer burden within a few months. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new…

Myeloma diagnosis can take over 5 months and require more than 4 medical consultations with more than 3 different specialists

Access, MPE, Myeloma, Patient evidenceLeave a comment

Brussels, 27 September 2022 – For some European myeloma patients, their diagnosis can take over 5 months, require more than 4 medical consultations and involve visits to at least 3 different medical specialists. These are some of the findings of pan-European research conducted by Myeloma Patients Europe (MPE) with the aim of exploring patient and doctor (haematologist) experiences of myeloma diagnosis. MPE ran a survey, and several focus groups and interviews, in which more than 600…

The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myeloma

Access, MyelomaLeave a comment

  The European Commission has approved marketing authorisation (e.g. a license) for melphalan flufenamide (also called melflufen), a drug marketed in Europe by Oncopeptides with the name of Pepaxti®. This follows the previous positive recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).